The top 10 takeover targets in biopharma | Fierce Biotech
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
Opinion: Three tech, three biotech companies that are top takeover targets in 2019 - MarketWatch
Bluebird Bio stock falls after FDA approves gene therapy
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first | Fierce Pharma
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
Will Bluebird Bio's Big Gamble Payoff? | Biotech Investing | Sick Economics
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout | Nasdaq
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
Bristol-Myers' Acquisition of - GuruFocus.com
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
bluebird bio: Hold, Wait To See If Revenue Ramps (NASDAQ:BLUE) | Seeking Alpha
National Resilience forks over $110M for North Carolina manufacturing site in bluebird bio cell therapy partnership | Fierce Pharma
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
MyoKardia & Eidos purchase; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin
Special episode - Bluebird Bio: What went wrong? -December 2021: by P4A Let's Talk Rare
Bluebird Bio $BLUE : r/HellsTradingFloor
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Bluebird Bio hits pause on rollout for ill-fated gene therapy Zynteglo as trial flags 2 cancer cases | Fierce Pharma
BLUEBIRDBIO
